Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

5,767JPY
26 May 2017
Change (% chg)

¥-33 (-0.57%)
Prev Close
¥5,800
Open
¥5,802
Day's High
¥5,828
Day's Low
¥5,757
Volume
1,823,900
Avg. Vol
2,110,596
52-wk High
¥5,856
52-wk Low
¥4,098

Latest Key Developments (Source: Significant Developments)

Takeda Pharmaceutical announces further details of transformational pharmaceutical sciences partnership with Bushu
Monday, 15 May 2017 05:20am EDT 

May 15(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it has entered into an agreement for an absorption-type company split with its wholly-owned subsidiary, SPERA PHARMA, Inc. on May 15.Says subsidiary was established as a succeeding company on April 20.Says it plans to transfer a part of Pharmaceutical Sciences businesses of the co to Bushu Pharmaceuticals Ltd. .Says it will transfer all of the issued shares in succeeding company to Bushu Pharmaceuticals Ltd. based on the share transfer agreement, on July 1.  Full Article

Takeda Pharmaceutical to transfer partial pharmaceutical research businesses to succeeding company
Monday, 15 May 2017 04:20am EDT 

May 15 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:* Says it established a succeeding company on April 27.* Says it will transfer a part of Takeda's pharmaceutical research businesses to the succeeding company, effective July 1.  Full Article

Takeda announces FDA accelerated approval of ALUNBRIG
Friday, 28 Apr 2017 06:13pm EDT 

April 28 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::Takeda announces FDA accelerated approval of ALUNBRIG(brigatinib).Says continued approval for ALK+ metastatic NSCLC indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Says serious adverse reactions occurred in 38% of patients in 90 mg group and 40% of patients in 90→180 mg group.Says fatal adverse reactions occurred in 3.7% of patients.Says the fatal adverse reactions consisted of pneumonia, sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis and urosepsis.Says FDA approval of ALUNBRIG was primarily based on results from pivotal phase 2 alta trial of brigatinib in adults.  Full Article

Takeda Pharmaceutical says splitting off partial Takeda Development Center Japan businesses to unit and plans JV with PRA Health Sciences
Friday, 7 Apr 2017 02:54am EDT 

Takeda Pharmaceutical Co Ltd <4502.T> : Says it plans to transfer partial Takeda Development Center Japan business related to clinical trials, pharmacovigilance services for both development and marketed products which are operated by TDC Japan, to its wholly owned unit as succeeding company which is established on March 30 . Business split-off will be effective on June 1 . Says co will sell 50 percent stake of shares in the unit (the succeeding company) to PRA Health Sciences Inc's unit Pharm Research Associates (UK) Ltd (PRA(UK)), at an undisclosed price, on June 1 .Through the transaction, the succeeding company will become a joint venture between Takeda and PRA(UK).  Full Article

Finch Therapeutics, Takeda collaborate to develop microbiome therapeutics in inflammatory bowel disease
Wednesday, 5 Apr 2017 07:20am EDT 

Takeda Pharmaceutical Co Ltd <4502.T> : Finch Therapeutics and Takeda announce global collaboration to develop microbiome therapeutics in inflammatory bowel disease (ibd) . Takeda Pharmaceutical Co Ltd says under terms of agreement, Takeda will make an upfront payment of $10 million to Finch . Takeda Pharmaceutical Co Ltd says further details of agreement were not disclosed .Takeda Pharmaceutical - Finch will be eligible for development, regulatory, commercial financial milestones & tiered royalties on worldwide net sales.  Full Article

Fujifilm Holdings says outcome of ToB offered by unit for shares in Wako Pure Chemical Industries Ltd
Tuesday, 4 Apr 2017 03:08am EDT 

Fujifilm Holdings Corp <4901.T> : Says 16.8 million shares of Wako Pure Chemical Industries Ltd were offered in a takeover bid by co's wholly owned unit from Feb. 27 to April 3 . Acquisition price at 8,535 yen per share . Settlement date starts from April 21 .Co's unit will own 93.50 percent stake (19,994 voting rights) in Wako Pure Chemical Industries Ltd, up from 14.82 percent stake (3,170 voting rights), after transaction.  Full Article

Takeda Pharmaceutical forms drug development company with two partners - Nikkei
Tuesday, 14 Mar 2017 03:40pm EDT 

Nikkei: Takeda pharmaceutical formed 10 billion yen ($87.2 million) drug development company with two partners .Takeda pharma owns 19.5% stake & public-private innovation network corp of japan holds 70.5% stake in scohia pharma, while medipal holds 10%.  Full Article

R&I removes Takeda Pharmaceutical from rating monitor and downgrades rating to "AA-" – R&I
Wednesday, 1 Mar 2017 01:33am EST 

Takeda Pharmaceutical Co Ltd <4502.T>: Rating and Investment Information, Inc. (R&I) removed the co from rating monitor - R&I . R&I downgraded its rating to "AA-" from "AA" - R&I .Rating outlook stable - R&I.  Full Article

Fujifilm Holdings offers ToB for 18.2 mln shares of Wako Pure Chemical Industries, Ltd.
Friday, 24 Feb 2017 01:18am EST 

Fujifilm Holdings Corp <4901.T>: Says the co offered a takeover bid for 18.2 million shares (or no less than 12.5 million shares) of Wako Pure Chemical Industries, Ltd., aiming to fully acquire it . Says offered purchase price at 8,535 yen per share . Takeover bid total amount at 155.47 billion yen . Offering period from Feb. 27 to April 3 .Settlement starts on April 21.  Full Article

Takeda Pharmaceutical to transfer consumer healthcare business to wholly owned unit
Monday, 20 Feb 2017 02:10am EST 

Takeda Pharmaceutical Co Ltd <4502.T>: Says the co plans to transfer domestic consumer healthcare business to its wholly owned unit, a Tokyo-based medical supplies firm .Says effective April 1.  Full Article

More From Around the Web

BRIEF-Teva Takeda Pharma to up overseas production of generic medication to cut costs - Nikkei

* Teva takeda pharma to increase overseas production of generic medication to cut costs per year as drug prices continue to decline - Nikkei Source text (http://s.nikkei.com/2qOMEN4) Further company coverage: